Trend of Non-contrast Chest Computed Tomography Use in the Lung Cancer Screening Era: SEER-Medicare 2008–2016

Szu Chun Yang; Cary Gross; Jung Der Wang; Shi Yi Wang

doi:10.1007/s11606-020-06586-4

Trend of Non-contrast Chest Computed Tomography Use in the Lung Cancer Screening Era: SEER-Medicare 2008–2016

Szu Chun Yang, Cary Gross, Jung Der Wang, Shi Yi Wang

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English
Pages (from-to)	3589-3591
Number of pages	3
Journal	Journal of General Internal Medicine
Volume	36
Issue number	11
DOIs	https://doi.org/10.1007/s11606-020-06586-4
Publication status	Published - 2021 Nov

All Science Journal Classification (ASJC) codes

Internal Medicine

Access to Document

10.1007/s11606-020-06586-4

Cite this

@article{bf23a8f2522849c8b0eede4115a3a1c3,

title = "Trend of Non-contrast Chest Computed Tomography Use in the Lung Cancer Screening Era: SEER-Medicare 2008–2016",

author = "Yang, {Szu Chun} and Cary Gross and Wang, {Jung Der} and Wang, {Shi Yi}",

note = "Funding Information: Dr. Yang reports grants from the Ministry of Science and Technology (MOST108-2918-I-006-006) and National Cheng Kung University Hospital (NCKUH-11002029) during the conduct of the study. Dr. Gross reports grants from Johnson & Johnson, NCCN Foundation (Pfizer/AstraZeneca), Flatiron Health, and Genentech outside the submitted work. Dr. S.Y. Wang reports grants from Genentech outside the submitted work. No other disclosures were reported. Funding Information: The collection of the California cancer incidence data used in this study was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885; the National Cancer Institute{\textquoteright}s Surveillance, Epidemiology and End Results Program under contract N01-PC-35136 awarded to the Northern California Cancer Center, contract N01-PC-35139 awarded to the University of Southern California, and contract N02-PC-15105 awarded to the Public Health Institute; and the Centers for Disease Control and Prevention{\textquoteright}s National Program of Cancer Registries, under agreement #U55/CCR921930-02 awarded to the Public Health Institute. The authors of this report are responsible for its content. The ideas and opinions expressed herein are those of the authors and endorsement by the State of California, Department of Public Health, the National Cancer Institute, and the Centers for Disease Control and Prevention or their Contractors and Subcontractors is not intended nor should be inferred. The authors acknowledge the efforts of the Applied Research Program, NCI; the Office of Research, Development and Information, CMS; Information Management Services (IMS), Inc.; and the Surveillance, Epidemiology, and End Results (SEER) Program tumor registries in the creation of the SEER-Medicare database. The interpretation and reporting of the SEER-Medicare data are the sole responsibility of the authors. Funding Information: The collection of the California cancer incidence data used in this study was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885; the National Cancer Institute{\textquoteright}s Surveillance, Epidemiology and End Results Program under contract N01-PC-35136 awarded to the Northern California Cancer Center, contract N01-PC-35139 awarded to the University of Southern California, and contract N02-PC-15105 awarded to the Public Health Institute; and the Centers for Disease Control and Prevention{\textquoteright}s National Program of Cancer Registries, under agreement #U55/CCR921930-02 awarded to the Public Health Institute. The authors of this report are responsible for its content. The ideas and opinions expressed herein are those of the authors and endorsement by the State of California, Department of Public Health, the National Cancer Institute, and the Centers for Disease Control and Prevention or their Contractors and Subcontractors is not intended nor should be inferred. The authors acknowledge the efforts of the Applied Research Program, NCI; the Office of Research, Development and Information, CMS; Information Management Services (IMS), Inc.; and the Surveillance, Epidemiology, and End Results (SEER) Program tumor registries in the creation of the SEER-Medicare database. The interpretation and reporting of the SEER-Medicare data are the sole responsibility of the authors.",

year = "2021",

month = nov,

doi = "10.1007/s11606-020-06586-4",

language = "English",

volume = "36",

pages = "3589--3591",

journal = "Journal of General Internal Medicine",

issn = "0884-8734",

publisher = "Springer New York",

number = "11",

}

TY - JOUR

T1 - Trend of Non-contrast Chest Computed Tomography Use in the Lung Cancer Screening Era

T2 - SEER-Medicare 2008–2016

AU - Yang, Szu Chun

AU - Gross, Cary

AU - Wang, Jung Der

AU - Wang, Shi Yi

N1 - Funding Information: Dr. Yang reports grants from the Ministry of Science and Technology (MOST108-2918-I-006-006) and National Cheng Kung University Hospital (NCKUH-11002029) during the conduct of the study. Dr. Gross reports grants from Johnson & Johnson, NCCN Foundation (Pfizer/AstraZeneca), Flatiron Health, and Genentech outside the submitted work. Dr. S.Y. Wang reports grants from Genentech outside the submitted work. No other disclosures were reported. Funding Information: The collection of the California cancer incidence data used in this study was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885; the National Cancer Institute’s Surveillance, Epidemiology and End Results Program under contract N01-PC-35136 awarded to the Northern California Cancer Center, contract N01-PC-35139 awarded to the University of Southern California, and contract N02-PC-15105 awarded to the Public Health Institute; and the Centers for Disease Control and Prevention’s National Program of Cancer Registries, under agreement #U55/CCR921930-02 awarded to the Public Health Institute. The authors of this report are responsible for its content. The ideas and opinions expressed herein are those of the authors and endorsement by the State of California, Department of Public Health, the National Cancer Institute, and the Centers for Disease Control and Prevention or their Contractors and Subcontractors is not intended nor should be inferred. The authors acknowledge the efforts of the Applied Research Program, NCI; the Office of Research, Development and Information, CMS; Information Management Services (IMS), Inc.; and the Surveillance, Epidemiology, and End Results (SEER) Program tumor registries in the creation of the SEER-Medicare database. The interpretation and reporting of the SEER-Medicare data are the sole responsibility of the authors. Funding Information: The collection of the California cancer incidence data used in this study was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885; the National Cancer Institute’s Surveillance, Epidemiology and End Results Program under contract N01-PC-35136 awarded to the Northern California Cancer Center, contract N01-PC-35139 awarded to the University of Southern California, and contract N02-PC-15105 awarded to the Public Health Institute; and the Centers for Disease Control and Prevention’s National Program of Cancer Registries, under agreement #U55/CCR921930-02 awarded to the Public Health Institute. The authors of this report are responsible for its content. The ideas and opinions expressed herein are those of the authors and endorsement by the State of California, Department of Public Health, the National Cancer Institute, and the Centers for Disease Control and Prevention or their Contractors and Subcontractors is not intended nor should be inferred. The authors acknowledge the efforts of the Applied Research Program, NCI; the Office of Research, Development and Information, CMS; Information Management Services (IMS), Inc.; and the Surveillance, Epidemiology, and End Results (SEER) Program tumor registries in the creation of the SEER-Medicare database. The interpretation and reporting of the SEER-Medicare data are the sole responsibility of the authors.

PY - 2021/11

Y1 - 2021/11

UR - http://www.scopus.com/inward/record.url?scp=85099533063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85099533063&partnerID=8YFLogxK

U2 - 10.1007/s11606-020-06586-4

DO - 10.1007/s11606-020-06586-4

M3 - Comment/debate

C2 - 33469753

AN - SCOPUS:85099533063

SN - 0884-8734

VL - 36

SP - 3589

EP - 3591

JO - Journal of General Internal Medicine

JF - Journal of General Internal Medicine

IS - 11

ER -

Trend of Non-contrast Chest Computed Tomography Use in the Lung Cancer Screening Era: SEER-Medicare 2008–2016

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Cite this